Skip to main content

Nocturia

Nocturia is the need to wake from sleep one or more times to void. A single nocturnal void is common, especially with aging, but two or more voids per night is the usual threshold for clinically meaningful bother, sleep disruption, fall risk, and health consequences.[1][2][3]

It can come from nocturnal urine overproduction, reduced bladder capacity, incomplete emptying, sleep apnea, insomnia, edema mobilization, diabetes, kidney disease, heart failure, medications, or mixed physiology.

Definition and Terminology​

Count nocturia episodes from sleep onset until the intention to rise; do not count the first morning void as a nocturia episode.[28] The first episode must be preceded by sleep, and each later episode must be followed by sleep or the intention to return to sleep. Voiding before initially falling asleep is not counted as nocturia. Distinguish awakenings driven by bladder symptoms from sleep disorders with opportunistic voiding, while recognizing that both can contribute.[1][2][28]

TermDefinitionPractical use
NocturiaWaking from sleep to void one or more timesSymptom; count episodes per night
Nocturnal polyuria (NP)Excessive urine production during the main sleep period; conventional NPi cutoffs are >20% in younger adults and >33% in older adults, but are not well validated[32]Most common physiologic driver; quantify with a bladder diary and state the threshold used[4]
Global polyuria24-hour urine output >40 mL/kg[32]Think diabetes mellitus, diabetes insipidus, polydipsia, excessive fluid intake
Reduced bladder capacityFunctional capacity too low for overnight urine productionOAB, BOO, cystitis, fibrosis, neurogenic bladder, pain syndromes
Nocturia index (Ni)Nocturnal urine volume / maximum voided volumeCompares urine production with functional capacity; it is not the observed void count
Nocturnal polyuria index (NPi)Nocturnal urine volume / 24-hour urine volumeQuantifies nocturnal urine fraction
First uninterrupted sleep period (FUSP)Time from sleep onset to first nocturnal voidSleep-quality outcome; often more meaningful than total void count

Epidemiology​

Nocturia is one of the most common lower urinary tract symptoms and rises sharply with age.[2][4][5]

GroupPattern
Young adultsOne nocturnal void is common; two or more voids are less common but still clinically important when bothersome
Women under midlifeOften report nocturia more frequently than similarly aged men
Older adultsPrevalence increases across sexes; many adults in their 70s and 80s wake at least once nightly
Men with LUTSNocturia is often attributed to BPH, but nocturnal polyuria and sleep disorders frequently dominate

Population-based data from China, South Korea, and Taiwan (adults aged 40 years or older) found nocturia with two or more voids in about 35% of men and 37% of women, and three or more voids in about 16% and 18%.[6] The EAU non-neurogenic female LUTS guideline summarizes two or more voids per night in 4-18% of women aged 20-40 years versus 28-62% of women aged 70 years or older.[29] Incidence increases with age; a meta-analysis of longitudinal cohorts found annual remission in 12.1% of people with nocturia.[7]

Risk factors associated with nocturia include older age, obesity, diabetes, hypertension, cardiovascular disease, obstructive sleep apnea, depression, erectile dysfunction, childhood enuresis history, and metabolic syndrome.[6][8]

Pathophysiology​

Nocturia reflects a mismatch between nocturnal urine production, bladder storage capacity, and sleep architecture.[9][10][11]

Nocturnal polyuria​

Nocturnal polyuria is excessive urine production during the main sleep period.[32] Mechanisms include:

  • Impaired nocturnal arginine vasopressin (AVP) rise. Less overnight water conservation
  • Peripheral edema mobilization. Leg fluid returns to the intravascular space when supine
  • Atrial natriuretic peptide release. Promotes natriuresis and diuresis
  • Obstructive sleep apnea. Negative intrathoracic pressure and hypoxia increase ANP and nocturnal urine production
  • Cardiovascular or renal disease. Daytime fluid retention with nighttime redistribution[10][11][12][13]

Reduced bladder capacity​

Nocturia can occur when the overnight bladder capacity is lower than the nocturnal urine load. Causes include OAB, detrusor overactivity, bladder outlet obstruction, high post-void residual, neurogenic bladder, painful bladder syndrome, radiation or inflammatory bladder fibrosis, and some nocturnal-specific capacity patterns.[9][14]

Global polyuria​

Global polyuria means the patient makes too much urine across the whole day, not just at night. Common causes include poorly controlled diabetes mellitus, diabetes insipidus, primary polydipsia, excessive fluid intake, hypercalcemia, and some renal concentrating disorders.[3][9]

Sleep disorders​

Some patients wake because of insomnia, arousal disorder, restless legs, pain, or obstructive sleep apnea, then void because they are awake. Others are awakened by bladder filling and then develop secondary sleep fragmentation. The relationship is often bidirectional.[2][15]

Mixed etiology​

Most clinically significant nocturia is mixed. A patient may have nocturnal polyuria from edema and OSA, reduced capacity from OAB, and incomplete emptying from BPH or underactive bladder. Treating only one axis explains many disappointments in nocturia care.[3][16]

The Sleep CALM framework is useful:

  • Sleep disorders
  • Comorbidities: cardiovascular, renal, endocrine, neurologic
  • Actions: fluids, caffeine, alcohol, salt, evening habits
  • Lower urinary tract dysfunction
  • Medications[15]

Health Consequences​

Nocturia is associated with sleep fragmentation, impaired daytime function, depression, falls, fractures, and mortality.[2][9]

ConsequenceEvidence signal
Sleep disruptionShorter FUSP and repeated waking correlate with poor sleep quality and daytime dysfunction
Falls and fracturesMeta-analysis shows increased risk of falls and a possible increase in fractures among patients with nocturia
MortalityMeta-analysis shows nocturia is associated with higher all-cause mortality; nocturia should trigger systemic evaluation
Work and cognitionSleep interruption worsens productivity, concentration, and quality of life

Diagnostic Evaluation​

History and Examination​

History points:

  • Number of nocturnal voids and timing of the first void
  • Whether the patient wakes to void or voids because already awake
  • Fluid, caffeine, alcohol, salt, and evening intake pattern
  • Diuretic timing and other medications
  • Snoring, witnessed apneas, morning headaches, daytime sleepiness, insomnia
  • Leg edema, heart failure, kidney disease, hypertension, diabetes
  • LUTS: urgency, frequency, UUI, weak stream, hesitancy, straining, incomplete emptying
  • UTIs, hematuria, pelvic pain, neurologic disease

Physical examination should look for peripheral edema, obesity or sleep-apnea phenotype, blood pressure abnormalities, cardiopulmonary signs, abdominal distension, pelvic organ prolapse when relevant, prostate enlargement when relevant, and focused neurologic findings.[3][9][15]

Frequency-Volume Chart​

A frequency-volume chart or bladder diary covering at least three days is the cornerstone test.[29][31] It should record:

  • Time and volume of each void
  • Sleep time and wake time
  • Fluid intake timing, type, and volume
  • Incontinence episodes and urgency when relevant
  • Diuretic timing

Derived calculations:

CalculationFormulaInterpretation
24-hour urine outputSum all voids after the first morning void on day 1 through and including the first morning void on day 2[32]>40 mL/kg suggests global polyuria
Nocturnal urine volumeNighttime voids plus first morning voidUsed for nocturnal polyuria calculation
NPiNocturnal urine volume / 24-hour urine volumeConventional thresholds are >20% in younger and >33% in older adults; these cutoffs are not well validated.[32]
MVVLargest single voided volumeProxy for functional bladder capacity
NiNocturnal urine volume / MVVCompares nocturnal production with functional capacity

The diary also prevents a common error: treating nocturia as OAB or BPH when the real problem is nighttime urine overproduction.[1][3][19]

Laboratory and Ancillary Testing​

Common tests include:

  • Urinalysis +/- urine culture
  • Serum sodium, creatinine/eGFR, glucose or A1c
  • Calcium when global polyuria is unexplained
  • PSA in selected men based on age, risk, and prostate evaluation
  • BNP or cardiac evaluation when heart failure is suspected
  • PVR when voiding symptoms, OAB medication, antidiuretic therapy, or outlet surgery is being considered

The EAU guideline (limited update 2026) strongly recommends a three-day bladder diary, a full history including screening for sleep disorders, and, when nocturia is the predominant symptom, consideration of renal function, thyroid function, HbA1c and calcium testing; it advises against a nocturnal-only diary in women (weak).[29] When storage symptoms or isolated nocturia predominate in a man with presumed BPH, the AUA 2026 BPH guideline advises a frequency-volume chart and reconsidering the diagnosis (idiopathic OAB, nocturnal polyuria, systemic disease).[30] Screen for OSA with STOP-BANG or equivalent when snoring, obesity, witnessed apneas, resistant hypertension, morning headaches, daytime sleepiness, or refractory nocturnal polyuria is present. Urodynamics are not routine for nocturia, but are appropriate when the diary and symptoms suggest BOO, detrusor underactivity, neurogenic dysfunction, refractory OAB, or unclear bladder capacity limitation.[9][15][20]

Management​

Behavioral and Comorbidity Treatment​

Initial management targets the driver identified by history and FVC:[29][31]

  • Reduce evening fluids, especially 2-4 hours before bedtime
  • Limit evening caffeine and alcohol
  • Reduce high evening salt intake
  • Move diuretics to mid- or late afternoon when medically appropriate
  • Elevate legs in the afternoon for dependent edema
  • Use daytime compression stockings for venous insufficiency or edema
  • Optimize diabetes, hypertension, CKD, heart failure, and sleep apnea
  • Treat constipation and mobility barriers
  • Improve bathroom safety: lighting, assistive devices, bedside commode when needed[3][15][21]

The individual lifestyle measures are largely consensus-based and their effects are not well quantified. The EAU guideline strongly recommends lifestyle advice and pelvic floor muscle training for women with nocturia and other storage LUTS (in a secondary analysis of a trial of 197 older women with urge or urge-predominant mixed incontinence, an eight-week multicomponent behavioral program including four biofeedback-assisted PFMT sessions reduced nocturia by a median 0.5 episodes per night among the 131 with baseline nocturia, more than oxybutynin or placebo)[34], and a sleep-clinic referral when history suggests OSA.[29] In men with persistent storage LUTS on an alpha-blocker, behavioral therapy was superior to oxybutynin for nocturia in a MOTIVE subgroup analysis.[30]

For edema-driven nocturnal polyuria, afternoon leg elevation and compression can shift diuresis earlier in the day. In selected patients, afternoon loop diuretics can mobilize fluid before sleep; EAU 2026 weakly recommends offering afternoon-dosed furosemide to women with nocturnal polyuria after counseling on benefits and risks.[29] Assess blood pressure, renal function, electrolytes, and fall risk.[3][29] The supporting randomized trial (furosemide 40 mg six hours before bedtime in older men) reduced nocturia by only about 0.5 episodes versus placebo among the 43 men who completed the study, and no comparable trial exists in women.[29]

Desmopressin for Nocturnal Polyuria​

Desmopressin is a synthetic AVP analogue that reduces nocturnal urine production. It is the most phenotype-specific medication for nocturia due to documented nocturnal polyuria.[4][19][22]

The US NOCDURNA sublingual formulation is no longer marketed in the US, although the equivalent product remains licensed in Europe and the UK as Noqdirna; formulations and microgram doses are not interchangeable. The former US NOCDURNA label limited treatment to adults with documented nocturnal polyuria and at least two nocturnal voids per night; confirm the formulation's indication and safety requirements before prescribing.[27] Detailed dosing belongs in the desmopressin pharmacology page.[27]

  • Ensure normal sodium before starting or restarting; recheck within one week, at one month, then periodically, more often with older age or other risk factors.
  • Contraindications include current or past hyponatremia, eGFR below 50 mL/min/1.73 m², heart failure, uncontrolled hypertension, polydipsia, SIADH, loop diuretics, systemic or inhaled glucocorticoids, and illnesses causing fluid or electrolyte imbalance. The NOCDURNA label separately advises against use in patients with a history of urinary retention or risk of increased intracranial pressure because of fluid retention; these are warnings, not listed contraindications.[27]
  • Minimize fluid intake from one hour before through eight hours after the dose; the label dose is once daily, one hour before bedtime.[27]

In three women-specific trials, desmopressin reduced nocturia with overall high-certainty evidence, showing a dose-response and greater sensitivity in women than men; EAU 2026 gives a strong recommendation to offer it for nocturnal polyuria after counseling about benefits and risks, including hyponatremia.[29] For women with OAB and nocturnal polyuria, EAU gives a weak recommendation for combination with an antimuscarinic; the combination evidence is low certainty.[29] Older age and low baseline sodium raise hyponatremia risk.[29] In three-month randomized NOCDURNA trials of adults with nocturnal polyuria and at least two nightly voids, desmopressin reduced nocturnal voids versus placebo by a mean 0.3/night in women (118 treated, 114 placebo) and 0.4/night in men (102 treated, 128 placebo).[27] A systematic review of randomized trials also found a longer first uninterrupted sleep period (FUSP); hyponatremia remains the main safety concern.[22][27] The 2023 AGS Beers Criteria alternatives paper recommends avoiding desmopressin for nocturia or nocturnal polyuria in older adults because safer non-drug approaches and comorbidity-directed treatments are preferred.[21][22][23]

OAB and Reduced Capacity Treatment​

For reduced-capacity storage symptoms, see the OAB & UUI treatment database for procedural comparisons.

When the diary shows small nocturnal voided volumes, urgency, or daytime storage symptoms, treat the storage phenotype:

  • Bladder training and urgency suppression
  • Pelvic-floor therapy when pelvic-floor overactivity or mixed incontinence is present
  • Beta-3 agonist when medication is appropriate, especially in older adults
  • Antimuscarinic therapy selectively, with caution about cognitive effects, constipation, dry mouth, and retention
  • Intradetrusor botulinum toxin or neuromodulation for refractory OAB or UUI after appropriate evaluation

Beta-3 agonists reduced nocturia more than antimuscarinics in a systematic review cited by the EAU guideline, and a small trial found mirabegron improved uninterrupted sleep in women where an oxybutynin patch did not. A placebo-controlled trial in women found about one fewer nocturnal episode with melatonin 2 mg for two weeks; EAU 2026 strongly recommends considering up to two weeks of melatonin when nocturia accompanies sleep disturbance, while its broader review evidence is low certainty.[29] Vaginal estrogen may improve reported nocturia in postmenopausal women, but the evidence is low certainty. In a 24-week active-comparator trial of 251 women, 51% using an estradiol ring and 54% using estriol pessaries reported relief; there was no untreated group.[33] EAU 2026 gives a weak offer recommendation after counseling.[29]

See Urgency Incontinence & OAB for the broader storage pathway.

Men With BPH or Outlet Symptoms​

Alpha-blockers, 5-alpha reductase inhibitors, and outlet procedures can improve nocturia when bladder outlet obstruction is a meaningful contributor, but many men continue to wake if nocturnal polyuria, OSA, edema, or insomnia is untreated.[24] The AUA 2026 guideline states that isolated nocturia without voiding LUTS is not a typical manifestation of BPH, and lists predominant nocturia or storage LUTS among the signs that should prompt reconsideration of the diagnosis when BPH treatment has not improved symptoms.[30]

The EAU 2026 male LUTS guideline makes these recommendations for men with nocturia:[31]

  • Treat the underlying causes, including behavioral, systemic and sleep disorders such as OSA, and lower urinary tract dysfunction (strong). Discuss behavioral changes to reduce nocturnal urine volume and improve sleep (strong).
  • Offer desmopressin for nocturia from nocturnal polyuria in men under 65 years (weak). Screen sodium at baseline, on day 3 and day 7, at 1 month and periodically thereafter, and more often in men over 65 or at increased hyponatremia risk (strong). Discuss benefit against risk, especially over 65 (strong). For low-dose desmopressin ODT, the men's 50 mcg and women's 25 mcg doses are desmopressin base equivalents of 55.3 and 27.7 mcg acetate, respectively; serum sodium must be normal before treatment at any age.[27][31]
  • In the pooled desmopressin ODT trials EAU cites, clinically significant hyponatremia occurred in 11% of men aged 65 or older versus 0% of men under 65 at 50 mcg.[31]
  • Offer an alpha blocker when nocturia accompanies voiding LUTS, an antimuscarinic when it accompanies OAB, and a 5-ARI when it accompanies LUTS with a prostate over 40 mL (all weak).[31] Do not offer PDE5 inhibitors for nocturia (weak). EAU notes that effect sizes for these drugs are small and that no studies addressed OAB drugs for nocturia specifically in men.

See Benign Prostatic Hyperplasia and Primary Bladder Neck Obstruction when the diary and flow and PVR suggest outlet disease.

Obstructive Sleep Apnea​

OSA treatment can improve nocturia, especially when nocturnal polyuria is present. CPAP reduces negative intrathoracic pressure, decreases ANP-mediated nocturnal diuresis, and improves sleep continuity.[12][20][25][26]

CPAP cohorts reported fewer nocturnal voids, lower nocturnal urine volume, and fewer patients with at least two nightly voids; in a separate three-month study with 40 completers, NPi also fell.[13][20][25][26]

Special Considerations​

Older and Frail Adults​

Prioritize fall prevention, lighting, mobility support, medication review, edema control, and systemic disease management. Avoid anticholinergic burden when possible. Desmopressin is usually a last-line or avoided option because hyponatremia can be catastrophic.[17][18][21]

Women​

Assess for OAB, nocturnal polyuria, sleep disorders, edema, genitourinary syndrome of menopause, prolapse, recurrent UTI, and pain syndromes. Vaginal estrogen can help GSM-associated urgency and frequency.

Men​

Use the diary before escalating BPH medications or surgery.[24]

Systemic Disease Signal​

New or worsening nocturia may be the first visible sign of sleep apnea, heart failure, CKD, diabetes, poorly controlled hypertension, edema, or medication harm. A urology visit should become the doorway to medical optimization when the diary points outside the bladder.

See Also​

References​

1. Van Kerrebroeck P, Andersson KE. "Terminology, epidemiology, etiology, and pathophysiology of nocturia." Neurourology and Urodynamics. 2014;33 Suppl 1:S2-S5. doi:10.1002/nau.22595

2. Bliwise DL, Wagg A, Sand PK. "Nocturia: a highly prevalent disorder with multifaceted consequences." Urology. 2019;133S:3-13. doi:10.1016/j.urology.2019.07.005

3. Oelke M, De Wachter S, Drake MJ, et al. "A practical approach to the management of nocturia." International Journal of Clinical Practice. 2017;71(11):e13027. doi:10.1111/ijcp.13027

4. Weiss JP, Everaert K. "Management of nocturia and nocturnal polyuria." Urology. 2019;133S:24-33. doi:10.1016/j.urology.2019.09.022

5. Bosch JLHR, Weiss JP. "The prevalence and causes of nocturia." The Journal of Urology. 2013;189(1 Suppl):S86-S92. doi:10.1016/j.juro.2012.11.033

6. Chow PM, Liu SP, Chuang YC, et al. "The prevalence and risk factors of nocturia in China, South Korea, and Taiwan: results from a cross-sectional, population-based study." World Journal of Urology. 2018;36(11):1853-1862. doi:10.1007/s00345-018-2329-0

7. Pesonen JS, Cartwright R, Mangera A, et al. "Incidence and remission of nocturia: a systematic review and meta-analysis." European Urology. 2016;70(2):372-381. doi:10.1016/j.eururo.2016.02.014

8. Azuero J, Santander J, Trujillo CG, et al. "Potential associations of adult nocturia: results from a national prevalence study." Neurourology and Urodynamics. 2021;40(3):819-828. doi:10.1002/nau.24624

9. Dani H, Esdaille A, Weiss JP. "Nocturia: aetiology and treatment in adults." Nature Reviews Urology. 2016;13(10):573-583. doi:10.1038/nrurol.2016.134

10. Birder LA, Van Kerrebroeck PEV. "Pathophysiological mechanisms of nocturia and nocturnal polyuria: the contribution of cellular function, the urinary bladder urothelium, and circadian rhythm." Urology. 2019;133S:14-23. doi:10.1016/j.urology.2019.07.020

11. Weiss JP, Monaghan TF, Epstein MR, Lazar JM. "Future considerations in nocturia and nocturnal polyuria." Urology. 2019;133S:34-42. doi:10.1016/j.urology.2019.06.014

12. Niimi A, Suzuki M, Yamaguchi Y, et al. "Sleep apnea and circadian extracellular fluid change as independent factors for nocturnal polyuria." The Journal of Urology. 2016;196(4):1183-1189. doi:10.1016/j.juro.2016.04.060

13. Miyazato M, Tohyama K, Touyama M, et al. "Effect of continuous positive airway pressure on nocturnal urine production in patients with obstructive sleep apnea syndrome." Neurourology and Urodynamics. 2017;36(2):376-379. doi:10.1002/nau.22936

14. Presicce F, Puccini F, De Nunzio C, et al. "Variations of nighttime and daytime bladder capacity in patients with nocturia: implication for diagnosis and treatment." The Journal of Urology. 2019;201(5):962-966. doi:10.1097/JU.0000000000000022

15. Monaghan TF, Weiss JP, Wein AJ, et al. "Sleep disorders, comorbidities, actions, lower urinary tract dysfunction, and medications ('Sleep C.A.L.M.') in the evaluation and management of nocturia: a simple approach to a complex diagnosis." Neurourology and Urodynamics. 2023;42(3):562-572. doi:10.1002/nau.25128

16. Yoon JH, Lee K, Park EJ, et al. "Analysis of changes in the pathophysiology of nocturia according to the number of nocturia episode, age, and gender using frequency volume charts: a retrospective observational study." Medicine. 2022;101(43):e31295. doi:10.1097/MD.0000000000031295

17. Pesonen JS, Vernooij RWM, Cartwright R, et al. "The impact of nocturia on falls and fractures: a systematic review and meta-analysis." The Journal of Urology. 2020;203(4):674-683. doi:10.1097/JU.0000000000000459

18. Pesonen JS, Cartwright R, Vernooij RWM, et al. "The impact of nocturia on mortality: a systematic review and meta-analysis." The Journal of Urology. 2020;203(3):486-495. doi:10.1097/JU.0000000000000463

19. Homma Y. "Classification of nocturia in the adult and elderly patient: a review of clinical criteria and selected literature." BJU International. 2005;96 Suppl 1:8-14. doi:10.1111/j.1464-410X.2005.05655.x

20. Vrooman OPJ, van Balken MR, van Koeveringe GA, et al. "The effect of continuous positive airway pressure on nocturia in patients with obstructive sleep apnea syndrome." Neurourology and Urodynamics. 2020;39(4):1124-1128. doi:10.1002/nau.24329

21. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." Journal of the American Geriatrics Society. 2025;73(9):2657-2677. doi:10.1111/jgs.19500

22. Ebell MH, Radke T, Gardner J. "A systematic review of the efficacy and safety of desmopressin for nocturia in adults." The Journal of Urology. 2014;192(3):829-835. doi:10.1016/j.juro.2014.03.095

23. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." Cochrane Database of Systematic Reviews. 2017;10:CD012059. doi:10.1002/14651858.CD012059.pub2

24. Orlando AP, Maciejko LA, Lerner LB. "Nocturia in men: is the prostate really to blame?" Urologic Clinics of North America. 2025;52(4):581-594. doi:10.1016/j.ucl.2025.07.011

25. Miyauchi Y, Okazoe H, Okujyo M, et al. "Effect of the continuous positive airway pressure on the nocturnal urine volume or night-time frequency in patients with obstructive sleep apnea syndrome." Urology. 2015;85(2):333-336. doi:10.1016/j.urology.2014.11.002

26. Margel D, Shochat T, Getzler O, Livne PM, Pillar G. "Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea." Urology. 2006;67(5):974-977. doi:10.1016/j.urology.2005.11.054

27. NOCDURNA (desmopressin acetate). US prescribing information. Sodium monitoring, contraindications and fluid precautions. DailyMed. Accessed September 11, 2026.

28. International Continence Society. Nocturia: current definition and explanatory notes. ICS terminology. Accessed September 11, 2026.

29. European Association of Urology. EAU Guidelines on Management of Non-neurogenic Female LUTS: limited update March 2026. Section 4.6 (nocturia). Guideline.

30. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026). Parts I–III. doi:10.1097/JU.0000000000005097.

31. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS. 2026 (March update). Official full guideline. See section 5.5.

32. Hashim H, Blanker MH, Drake MJ, et al. "International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function." Neurourol Urodyn. 2019;38(2):499–508. doi:10.1002/nau.23917

33. Lose G, Englev E. "Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms." BJOG. 2000;107(8):1029-1034. doi:10.1111/j.1471-0528.2000.tb10408.x

34. Johnson TM 2nd, Burgio KL, Redden DT, Wright KC, Goode PS. "Effects of behavioral and drug therapy on nocturia in older incontinent women." J Am Geriatr Soc. 2005;53(5):846-850. doi:10.1111/j.1532-5415.2005.53260.x